Apogee Therapeutics stock price target raised by RBC Capital to $70
PositiveFinancial Markets

RBC Capital has raised its stock price target for Apogee Therapeutics to $70, reflecting growing confidence in the company's potential. This adjustment is significant as it indicates a positive outlook for Apogee's future performance, which could attract more investors and boost market interest. Such developments are crucial for the company as they navigate the competitive landscape of the biotech industry.
— Curated by the World Pulse Now AI Editorial System







